<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYDROQUINONE</span><br/>(hye'droe-kwin-one)<br/><span class="topboxtradename">Eldopaque, </span><span class="topboxtradename">Eldoquin, </span><span class="topboxtradename">Esoterica Regular, </span><span class="topboxtradename">Melanex, </span><span class="topboxtradename">Porcelana, </span><span class="topboxtradename">Solaquin<br/></span><b>Classifications:</b> <span class="classification">skin and mucous membrane agent</span>; <span class="classification">depigmentor</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1.5%, 2%, 3%, 4% cream, gel, solution</p>
<h1><a name="action">Actions</a></h1>
<p>Topical agent that causes reversible bleaching of hyperpigmented skin due to increased melanin. Interferes with formation
         of new melanin but does not destroy existing pigment. Depresses melanin synthesis and melanocytic growth, possibly by increasing
         excretion of melanin from melanocytes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Interferes with formation of new melanin but does not destroy existing pigment.</p>
<h1><a name="uses">Uses</a></h1>
<p>Gradual bleaching of hyperpigmented skin conditions such as chloasma or melasma, severe freckling, senile lentigines (age
         spots or liver spots). Also as an antioxidant in topical preparations. Some formulations include a sunscreening agent (e.g.,
         Porcelana with Sunscreen, Mercolized Cocrema, Pabaquinone, and Solaquin).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prickly heat, sunburn, irritated skin, depilatory usage; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Safe use during pregnancy (category C) or in children <img src="../images/special/lesserorequal.gif"/>12 y is not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Bleaching of Hyperpigmented Skin</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply thin layer and rub into hyperpigmented skin b.i.d., a.m. and p.m.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Test skin for sensitivity before treatment is initiated. Apply small amount of drug (about 25 mm in diameter) to an unbroken
            patch of skin and check in 24 h. Do not use drug if vesicle formation, itching, or excessive inflammation occur. Minor redness
            is not a contraindication.
         </li>
<li>Limit applications to an area no larger than that of face and neck.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Dryness and fissuring of paranasal and infraorbital areas, inflammatory reaction, erythema; stinging, tingling, burning sensations;
      irritation, sensitization, and contact dermatitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: In general, complete depigmentation occurs in 14 mo and lasts 26 mo after
            hydroquinone is discontinued. Once desired results are obtained, reduce amount and frequency of applications to the least
            that will maintain depigmentation.
         </li>
<li>Discontinue if bleaching or skin lightening does not occur after 2 or 3 mo of therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use a sunscreen agent or a hydroquinone formulation containing a sunscreen for daytime applications.</li>
<li>Wash drug off if rash or irritation develops and consult physician.</li>
<li>Avoid contact with the eyes and not to use on open lesions, sunburned, irritated, or otherwise damaged skin.</li>
<li>Continue use of protective clothing and sunscreening agent after treatment is terminated to reduce possibility of repigmentation.</li>
<li>Do not breast feed while taking/using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>